|Bid||0.00 x 3000|
|Ask||0.00 x 4000|
|Day's Range||7.08 - 7.50|
|52 Week Range||4.12 - 8.13|
|Beta (3Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Fitzgerald Global.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever. Yellow fever represents a significant unmet medical need and a new potential use of galidesivir. With this additional $3.5 million contract amendment, the NIAID development contract for galidesivir now totals $43.0 million.
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
BioCryst Pharmaceuticals Inc. shares (bcrx) surged more than 6% premarket on the news that it has won a $35 million, five-year contract from the Centers for Disease Control and Prevention for up to 50,000 doses of its antiviral flu therapy Rapivab. The CDC will place the medication in the Strategic National Stockpile, a supply of potentially life-saving medicines for use in a public-health emergency. Rapivab is used to treat acute flu in patients two years and older who have shown symptoms for more than two days.
BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc. (BCRX), please note that in the first line of the table, the values for the change from baseline in VAS score through 4 hours under BCX7353 Treated Attacks and Placebo Treated Attacks are numbers, not percentages as previously published. Please also note a footnote has been added to the end of the table within the release, which notes baseline composite VAS scores for both BCX7353 treated attacks and placebo treated attacks. RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p
BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p
RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018-- BioCryst Pharmaceuticals, Inc. today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati ...
BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 19 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018-- BioCryst Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2018.. “Building on the clear direction from our shareholders ...
BioCryst Pharmaceuticals, Inc. (BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.
BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). Fast Track Designation provides opportunities for frequent interactions with the FDA during development of a product candidate and provides the opportunity for priority review if supported by clinical data at the time of the new drug application (NDA) submission.